Form 4: Pharma-Bio Serv Director Acquires 20,000 Stock Options

Director Dov Perlysky acquired 20,000 stock options in Pharma-Bio Serv, Inc. with a vesting schedule over two years.

Summary

• Dov Perlysky, a director at Pharma-Bio Serv, Inc., has acquired 20,000 stock options.
• The options have an exercise price of $0.49 per share.
• The options vest in two equal installments on July 10, 2025 and July 10, 2026.
• The options expire on January 10, 2030.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock options, which is neither particularly positive nor negative. It indicates standard corporate governance practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive.
• The vesting schedule of two years is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price of $0.49 is specific to this grant and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the company performs well and the options are exercised at a profit.

Key Dates

Keywords

stock options, director, insider trading, equity, Pharma-Bio Serv, PBSV